Efficacy and Safety of Neauvia Intense in Correcting Moderate-to-Severe Nasolabial Folds: A Post-Market, Prospective, Open-Label, Single-Centre Study
DOI: https://doi.org/10.2147/ccid.s460973
2024-06-11
Clinical Cosmetic and Investigational Dermatology
Abstract:Nicola Zerbinati, 1 Anna P&lstrokatkowska, 2 Stefania Guida, 3, 4 Giorgio Stabile, 3, 4 Roberto Mocchi, 5 Chiara Barlusconi, 6 Sabrina Sommatis, 5 Leonardo Garutti, 7 Raffaele Rauso, 8 Giovanna Cipolla, 9 Luca Bettolini, 10, &ast Stefano Bighetti 10, &ast 1 Dermatology Unit, University of Insubria, Varese, Italy; 2 Dermatology Unit, Anclara Health &Aesthetics, Warsaw, Poland; 3 Dermatology Unit, Università Vita-Salute San Raffaele, Milan, Italy; 4 Dermatology Clinic, IRCCS San Raffaele Scientific Institute, Milan, Italy; 5 Microbiology and Biochemistry Department, UB-CARE S.r.l.-Spin-off, University of Pavia, Pavia, Italy; 6 Department of Biomedical Sciences and Human Oncology, University of Bari, Bari, Italy; 7 Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy; 8 Maxillofacial Surgery Unit, Clinica Parioli, Rome, Italy; 9 Dermatology Unit, Centro Medico Polispecialistico, Pavia, Italy; 10 Dermatology Unit, University of Brescia, Brescia, Italy &astThese authors contributed equally to this work Correspondence: Luca Bettolini; Stefano Bighetti, Dermatology Unit, University of Brescia, Brescia, 25123, Italy, Tel +39 030 3995301, Fax +39 030 399505, Email ; Purpose: This prospective, single-center study aims to evaluate the safety and effectiveness of NEAUVIA Intense, a PEG cross-linked polymeric hydrogel, in correcting moderate-to-severe nasolabial folds (NLF) in a routine clinical setting. The study investigates the aesthetic outcomes, patient satisfaction, and adverse events associated with the injectable filler. Patients and Methods: Seventy patients were initially enrolled, with 60 meeting study parameters. The post-market study involved a single session treatment, employing NEAUVIA Intense on each side of the NLF. Assessments utilized the Modified Fitzpatrick Wrinkle Scale (MFWS), Global Aesthetic Improvement Scale (GAIS), and Visual Analogical Scale (VAS). Results: The study demonstrated a statistically significant improvement in tissue depression immediately post-injection (p < 0.001), with sustained effects up to 6 months. MFWS assessments revealed that responder patients were 96.6% immediately after treatment, 76.6% one month, 48.3% after 3 months, and 28.3% at 6 months (p < 0.001). Additionally, there was a significant change in the frequency distribution of MFWS scores post-treatment (p < 0.001), with the majority of patients experiencing improvement in tissue depression. Maximum improvement was observed at 30- and 90-days post-treatment based on GAIS assessments. Patient and physician satisfaction, measured by VAS, remained stable over time, with fluctuations at 4 and 24 weeks after treatment (p < 0.001, Anova; p < 0.05, Wilcoxon). Throughout the entire follow-up duration of the patients enrolled in the study, no adverse effects related to the use of the product were observed. Conclusion: NEAUVIA Intense proved to be an effective solution for correcting NLF, providing significant and lasting improvements in tissue depression and aesthetic outcomes. The study underscores the necessity for continuous assessment in aesthetic medicine to align outcomes with evolving patient expectations and optimize long-term results. The findings contribute to the understanding of this specific hydrogel filler and highlight the broader context of injectable fillers in comprehensive facial aesthetic strategies. Keywords: dermal fillers, nasolabial folds, hyaluronic acid fillers, PEG cross-linked hydrogel, facial aging A novel branch of aesthetic medicine has emerged, offering a minimally invasive alternative to plastic surgery for addressing facial ageing. This specialized field focuses on techniques like intra-dermal or subcutaneous filler injections, particularly hyaluronic acid (HA) fillers, known for their remarkable aesthetic improvements with minimal downtime. 1–3 Dermal fillers, classified as class III medical devices, effectively restore facial volume and treat aesthetic defects such as wrinkles and scars. In particular, the nasolabial folds (NLF) are deep wrinkles located from the side of the nose to the corner of the mouth, commonly known as "laugh lines", and they change with age due to the loss of the integrity of the underlying tissues and of the volume itself, due to the decrease in HA and the alteration of collagen and tissue elasticity. 4–8 These "smile lines" can already be seen in younger adulthood, but this occurs mostly in the 40–50 age group. Injectable -Abstract Truncated-
dermatology